Skip to main content
. Author manuscript; available in PMC: 2023 Jan 5.
Published in final edited form as: Clin Cancer Res. 2022 Jun 2;28(16):3618–3629. doi: 10.1158/1078-0432.CCR-21-3189

Figure 6. Molecular portraits of a HER2-enriched patient with acquired endocrine resistance.

Figure 6

A, Box plots indicating median score and inter-quartile range of VAF of detected variants stratified by synonymous and nonsynonymous variants. B, Heatmap showing VAF of nonsynonymous variants of Pan-Cancer drivers. C, Heatmap showing gene expression of hormone receptors and key signaling pathways. D, Heatmap showing copy number landscapes of all tumors from the patient.